Expenditures and prices of antihyperglycemic medications in the United States
Rising out-of-pocket costs in people with type 2 diabetes have been reported in the United States. Although past studies have described per-person changes in excess medical spending of US adults with diabetes on prescription medications, they have not reported trends in expenditures for different classes of antihyperglycemic medications that simultaneously consider changes in use and price. Using a nationally representative household survey data of US, this project describes and compares trends in expenditure and price of different antihyperglycemic medications in US from 2002 to 2013, with a specific focusing on insulin.
Elbert S. Huang, Department of Medicine, University of Chicago, Chicago, Illinois
William H. Herman, School of Public Health, University of Michigan, Michigan
This research was partly supported by grant 5R01DK090435-02 from the National Institutes of Health and grants 1028335 and 1079621 from the National Health and Medical Research Council.